Dr. Mims on the Current Challenges With Myelofibrosis

Alice S. Mims, MD
Published: Thursday, Oct 26, 2017



Alice S. Mims, MD, assistant professor of medicine, Ohio State University Comprehensive Cancer Center, discusses the current challenges with myelofibrosis.

Most patients are not candidates for allogeneic transplants, which is the only myelofibrosis therapy. In addition, there is no therapy that has proven to reverse fibrosis.

Only about 10% to 20% of patients with myelofibrosis show signs of myelofibrosis risk factors prior to diagnosis. The risk factor is if you have another myeloid malignancy, specifically myeloproliferative disorders, such as polycythemia vera or essential thrombocythemia.


Alice S. Mims, MD, assistant professor of medicine, Ohio State University Comprehensive Cancer Center, discusses the current challenges with myelofibrosis.

Most patients are not candidates for allogeneic transplants, which is the only myelofibrosis therapy. In addition, there is no therapy that has proven to reverse fibrosis.

Only about 10% to 20% of patients with myelofibrosis show signs of myelofibrosis risk factors prior to diagnosis. The risk factor is if you have another myeloid malignancy, specifically myeloproliferative disorders, such as polycythemia vera or essential thrombocythemia.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x